10-Q Filing

GUARDANT HEALTH, INC. CIK: 1576280 Q1 2022

Filing Information

Form Type	10-Q
Accession Number	`0001576280-22-000026`
Period End Date	20220331
Filing Date	20220505
Fiscal Year	2022
Fiscal Period	Q1
XBRL Instance	gh-20220331_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 83 Income Statement 46 Cash Flow Statement 83 Stockholders Equity 23 Comprehensive Income 14

Balance Sheet 83 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$869.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$492.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$573.60M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$388.66M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$440.55M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$97.65M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$84.33M	USD	Point-in-time
Inventory	`InventoryNet`	$36.61M	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory	`InventoryNet`	$30.67M	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$53.05M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$30.07M	USD	Point-in-time
Preferred stock issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.11B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.11B	USD	Point-in-time
Preferred stock outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$588.45M	USD	Point-in-time
Preferred stock outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$698.03M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$151.32M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$124.46M	USD	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$189.44M	USD	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$188.61M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	101.90M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$14.21M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	101.77M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$13.73M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	101.77M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	101.90M	shares	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Assets	`Assets`	$2.20B	USD	Point-in-time
Assets	`Assets`	$2.13B	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$70.92M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$60.94M	USD	Point-in-time
Liabilities	`Liabilities`	$1.60B	USD	Point-in-time
Liabilities	`Liabilities`	$1.56B	USD	Point-in-time
Total Assets	`Assets`	$2.20B	USD	Point-in-time
Total Assets	`Assets`	$2.13B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$17.58M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$32.23M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$42.50M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$56.16M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$51.85M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$45.28M	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$10.57M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$11.33M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$228.81M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$194.69M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.13B	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.14B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$225.38M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$226.05M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$3.93M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$6.91M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.60B	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.56B	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2022, and December 31, 2021; 101,895,835 and 101,767,446 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2022, and December 31, 2021; 101,895,835 and 101,767,446 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.66B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.68B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.76M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-18.31M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.13B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.01B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$847.05M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.30B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$533.04M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$645.00M	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.13B	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.20B	USD	Point-in-time

Income Statement 46 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$63.73M	USD	1 Quarter
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$84.14M	USD	1 Quarter
Development services and other	`RevenueFromDevelopmentServices`	$11.96M	USD	1 Quarter
Development services and other	`RevenueFromDevelopmentServices`	$14.94M	USD	1 Quarter
Total revenue	`Revenues`	$78.67M	USD	1 Quarter
Total revenue	`Revenues`	$96.10M	USD	1 Quarter
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$30.68M	USD	1 Quarter
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$23.59M	USD	1 Quarter
Cost of development services and other	`CostOfDevelopmentServices`	$5.16M	USD	1 Quarter
Cost of development services and other	`CostOfDevelopmentServices`	$1.30M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$55.51M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$81.76M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$64.43M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$34.34M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$67.94M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$41.27M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$219.44M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$186.53M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-123.34M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-107.86M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$778.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.55M	USD	1 Quarter
Interest expense	`InterestExpense`	$646.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$644.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-290.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-48.00K	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-123.25M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-107.25M	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$110.00K	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$-24.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-123.23M	USD	1 Quarter
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$2.30M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-109.66M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-123.23M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-123.23M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-109.66M	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-1.09	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-1.21	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-1.09	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-1.21	USD	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.85M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	100.95M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.85M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	100.95M	shares	1 Quarter

Cash Flow Statement 83 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-123.23M	USD	1 Quarter
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$7.20M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$5.01M	USD	1 Quarter
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$6.95M	USD	1 Quarter
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$3.93M	USD	1 Quarter
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$2.39M	USD	1 Quarter
Non-cash stock-based compensation	`ShareBasedCompensation`	$55.07M	USD	1 Quarter
Non-cash stock-based compensation	`ShareBasedCompensation`	$24.80M	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$642.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$641.00K	USD	1 Quarter
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-2.45M	USD	1 Quarter
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-3.26M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	-	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$-21.00K	USD	1 Quarter
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-5.26M	USD	1 Quarter
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-13.30M	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$5.94M	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$6.16M	USD	1 Quarter
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-521.00K	USD	1 Quarter
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-21.88M	USD	1 Quarter
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$-3.85M	USD	1 Quarter
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$-1.20M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-753.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$11.99M	USD	1 Quarter
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$8.90M	USD	1 Quarter
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$13.66M	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$4.40M	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$8.02M	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-2.76M	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-3.11M	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-190.00K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-757.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-28.62M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-16.29M	USD	1 Quarter
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$163.74M	USD	1 Quarter
Purchase of marketable securities	`PaymentsToAcquireMarketableSecurities`	$70.65M	USD	1 Quarter
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$204.11M	USD	1 Quarter
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$310.00M	USD	1 Quarter
Purchase of non-marketable equity and other related investments	`PaymentsToAcquireEquitySecuritiesFvNi`	$12.75M	USD	1 Quarter
Purchase of non-marketable equity and other related investments	`PaymentsToAcquireEquitySecuritiesFvNi`	-	USD	1 Quarter
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$9.59M	USD	1 Quarter
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$22.70M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$110.81M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$123.87M	USD	1 Quarter
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$18.00K	USD	1 Quarter
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$55.00K	USD	1 Quarter
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$963.00K	USD	1 Quarter
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$4.46M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$957.00K	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$73.58M	USD	1 Quarter
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	-	USD	1 Quarter
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	$784.00K	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-69.95M	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-12.00K	USD	1 Quarter
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-792.00K	USD	1 Quarter
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-1.09M	USD	1 Quarter
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$36.54M	USD	1 Quarter
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$81.39M	USD	1 Quarter
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$573.67M	USD	Point-in-time
Cash, cash equivalents and restricted cashBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$869.52M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$573.67M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$869.52M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$3.94M	USD	1 Quarter
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$170.85M	USD	1 Quarter
Purchase of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$19.75M	USD	1 Quarter
Purchase of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$5.88M	USD	1 Quarter
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	-	USD	1 Quarter
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$238.00K	USD	1 Quarter
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$869.37M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$492.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$573.60M	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$144.00K	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$69.00K	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$573.67M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$869.52M	USD	Point-in-time

Stockholders Equity 23 line items

Line Item	Tag	Value	Unit	Period
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-2.30M	USD	1 Quarter
Beginning balance	`StockholdersEquity`	$847.05M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$533.04M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$645.00M	USD	Point-in-time
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	105,218.00	shares	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$963.00K	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$4.46M	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$8.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$13.00K	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$73.58M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$957.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$55.07M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$24.80M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-2.30M	USD	1 Quarter
Other comprehensive loss, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-1.79M	USD	1 Quarter
Other comprehensive loss, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-13.55M	USD	1 Quarter
Net loss	`ProfitLoss`	$-123.23M	USD	1 Quarter
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Ending balance	`StockholdersEquity`	$847.05M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$533.04M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$645.00M	USD	Point-in-time

Comprehensive Income 14 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-123.23M	USD	1 Quarter
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-706.00K	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-12.76M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.09M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-792.00K	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-1.79M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-13.55M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-109.15M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-136.78M	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$2.30M	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-111.45M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-136.78M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.